The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications - Test2 - elhamkhani - TriplyDB

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

http://www.wikidata.org/entity/Q24605052

about

Perspectives on anti-CD47 antibody treatment for experimental cancer Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy Structures of CD200/CD200 Receptor Family and Implications for Topology, Regulation, and Evolution Polymorphisms in the Human Inhibitory Signal-regulatory Protein Do Not Affect Binding to Its Ligand CD47 Lymphoma: immune evasion strategies CD47 expression in cryopreserved equine cutaneous masses and normal skin Dissection of agonistic and blocking effects of CD200 receptor antibodies Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans Splenic Dendritic Cells Survey Red Blood Cells for Missing Self-CD47 to Trigger Adaptive Immune Responses.Antibody Therapies in Cancer.Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells.Competing views on cancer.Macrophages in multiple myeloma: emerging concepts and therapeutic implications.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients Silencing of CD47 and SIRPα by Polypurine reverse Hoogsteen hairpins to promote MCF-7 breast cancer cells death by PMA-differentiated THP-1 cells Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.Pathway-gene identification for pancreatic cancer survival via doubly regularized Cox regression Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.CD47 regulates the phagocytic clearance and replication of the Plasmodium yoelii malaria parasite Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer.CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells CD47 Promotes Protective Innate and Adaptive Immunity in a Mouse Model of Disseminated Candidiasis.Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.Loss of Cell Surface CD47 Clustering Formation and Binding Avidity to SIRPα Facilitate Apoptotic Cell Clearance by Macrophages Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo.A fully human anti-CD47 blocking antibody with therapeutic potential for cancer Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals.A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells Original insights on thrombospondin-1-related antireceptor strategies in cancer.Development of anti-CD47 single-chain variable fragment targeted magnetic nanoparticles for treatment of human bladder cancer.Detecting cell-in-cell structures in human tumor samples by E-cadherin/CD68/CD45 triple staining.Photodynamic-therapy Activates Immune Response by disrupting Immunity Homeostasis of Tumor Cells, which Generates Vaccine for Cancer Therapy Secreted Thrombospondin-1 Regulates Macrophage Interleukin-1β Production and Activation through CD47.Immunoregulatory CD4(-)CD8(-) T cells as a potential therapeutic tool for transplantation, autoimmunity, and cancer.

P2860

Q24602779-1A87212D-768F-4EEF-BD37-F399928399FE Q26768652-C8689AEB-E284-464B-9896-0C14957B2C58 Q26780387-2671FB7E-11AA-4420-BCBD-4AA2E727BB93 Q26829987-B889B518-9BAC-40F4-BFB1-D4CB6C81E8F3 Q27021570-3D71AA58-FE1D-40BE-B004-4C67FAB6CAEE Q27677459-F5BEB028-4D13-4468-8EDF-36EFC16BA028 Q27681812-EB38C6C1-974E-4849-A4B9-87F96BCB7FED Q28080705-4528FF76-1C21-4AA1-BD48-DA90CC046DDA Q28275412-D763B1B5-253D-4CBE-8432-6DF38D673F35 Q28488034-8F98C099-9221-4C8C-9DFC-E1D0D00C58C1 Q28488566-90DEE2C4-A471-492F-9AA7-97AF884112ED Q28543785-D4848D8D-978B-49A5-9599-7493A2555096 Q30670402-B3BACD83-03F7-4317-89C6-8EE3DD5D2E74 Q31104000-B9D4D6AB-2021-437D-B47E-ABC2F58408E3 Q33586204-19E66976-107C-4AE5-8B27-78DD9492B3F0 Q34060169-F34D90F6-9FF2-4A8F-A605-F107F8494ACA Q34329242-FAC15477-FEAC-4DFB-ADDB-05C5934EE087 Q34361976-D033202E-2CDD-4116-998B-54F40B1A40CB Q34483478-0B9C32FC-949A-4FAB-A165-E595B74E1907 Q34541210-ECBCBB11-D720-412A-B4C0-E981E0FBC031 Q34548156-D636C71F-1ED6-4A69-B9A1-431C7691D02A Q34553348-2EFA12FB-226B-4404-8C0C-3CCADE7C7CAE Q35102086-3239ABF7-6297-4BA3-A3EF-C4412ECD8B9B Q35119802-063033A4-0E30-428D-9078-D10B4AA2377E Q35189895-1CB3F51B-F057-4EFF-979B-0756EB626762 Q35554493-6391C266-E348-4B75-834A-8BF953BCEF43 Q35563107-DB5CF161-8BD2-47A3-BE63-C9599BB6B74C Q35648733-CB4CF0DC-0181-4D7B-9497-A2F5F0E7C986 Q35781873-75319CF8-598C-43E4-A57F-118059425D72 Q35815741-A5667C5F-EB2F-4E24-AC15-D1EE6C2A58F0 Q35993525-5F562932-6A5D-47DC-A38F-8471E3A8C67A Q36198093-9D8198F3-E3A0-41BD-8472-4C57F4CED3F5 Q36208486-5E95395C-4FD8-4475-8A44-F4A3D963231F Q36216038-E9147690-413B-44FF-B7C6-388B303F19D3 Q36221374-301C3216-D553-43D4-8AE0-1CE6F8CFCB5F Q36276770-720F874F-A85E-4ABA-A98D-2DC5DF50DEEF Q36299664-558D430D-12AE-4DCC-891A-D2E93BFB4BF6 Q36372462-8134C8AE-89F8-469F-8774-30128672E688 Q36507239-D9D8AC7B-67B3-4512-808A-B980F420CDA2 Q36557519-C4B2A23B-352B-47C3-B7A2-CB40706AD8BA

P2860

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

http://www.wikidata.org/entity/Q24605052

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@ast

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@en

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@nl

type

label

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@ast

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@en

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@nl

prefLabel

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@ast

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@en

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@nl

P1433

Q24605052-CA91B3B2-2133-4065-8316-5F5B38F327B9

P1476

Q24605052-775B13EB-7171-46CD-B64E-088CB1D4C0FE

P2093

Q24605052-1DA60BAA-E079-4AD6-9472-3D0C55DBF322

Q24605052-BE782A63-70E2-4D72-A36C-A87B7663E946

Q24605052-D9342734-4A20-489B-9063-B18453B28922

P2860

Q24605052-0673F6B5-C25C-4F08-8388-0173D924BC2C

Q24605052-084AB32C-9577-4F96-AD75-107EC54C32A2

Q24605052-0BCD426B-8EF0-4895-9627-EA957E2C69F2

Q24605052-1B61F542-82EB-487D-BDC1-0E7830386CCA

Q24605052-1F554EB3-21B9-4ECD-B30A-A55F2330F58B

Q24605052-22B1BE8A-978B-427E-B72B-7266D892470D

Q24605052-22B6C192-C2BD-49E0-B931-DBD1ED2E613F

Q24605052-22DF388D-6D19-4D4B-A037-FBFFF64046E6

Q24605052-24D25BF5-FAFD-44F8-AAFC-8D0E2FE00FA6

Q24605052-3592F4C3-D9FD-44D1-BCBB-696D3E926C4B

P304

Q24605052-C903F774-5D10-458B-9DA6-E0D22C63BC75

P31

Q24605052-7614F337-ED3D-4877-B70A-461BCBBCF75C

P3181

Q24605052-6EB003E6-1FEB-48F0-A6D7-DDE033BFA431

P356

Q24605052-09B2C215-CB13-4FA9-B3F3-1D3E53B87AA9

P407

Q24605052-B5C4EB77-2653-4368-92A3-24E9B5338AF7

P433

Q24605052-6E9E3133-5F35-40B9-B694-C3AE0FFC3D00

P478

Q24605052-3F5AB3A7-D510-4A0A-8419-08A30775A332

P577

Q24605052-59C08610-1116-4B32-B4DE-ABEEA65A73BE

P5875

Q24605052-C72E7B9B-4417-4AC1-99F0-66959C418B32

P698

Q24605052-E91CD5AD-E10B-4C27-B58C-BA44B616E140

P932

Q24605052-7798654D-7E46-4661-A56A-8CAEEDE675D2

P3181

P356

J.COI.2012.01.010

P1433

Current Opinion in Immunology

P1476

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

@en

P2093

Irving L Weissman

http://www.w3.org/2001/XMLSchema#string

Mark P Chao

http://www.w3.org/2001/XMLSchema#string

Ravindra Majeti

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

CD47 regulates bone mass and tumor metastasis to bone

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling

CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis

Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly

Role of CD47 as a marker of self on red blood cells

CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia

P304

225-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2233899

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.COI.2012.01.010

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221810523

http://www.w3.org/2001/XMLSchema#string

P698

22310103

http://www.w3.org/2001/XMLSchema#string

P932

3319521

http://www.w3.org/2001/XMLSchema#string